By proceeding, you agree to our Terms of Use and Privacy Policy.
Danette Daniels, Ph.D., joined Foghorn Therapeutics in February 2022 as VP of the Protein Degrader Platform. She brings more than 20 years of cancer research experience in focused areas of epigenetics, small molecules, and targeted protein degradation.
Talks About #assaydevelopment #drugdiscovery
Preferred Locations #NorthAmerica